vs
Side-by-side financial comparison of ASTRAZENECA PLC (AZN) and Procter & Gamble (PG). Click either name above to swap in a different company.
Procter & Gamble is the larger business by last-quarter revenue ($22.2B vs $14.5B, roughly 1.5× ASTRAZENECA PLC). Procter & Gamble runs the higher net margin — 19.4% vs 16.9%, a 2.5% gap on every dollar of revenue. On growth, ASTRAZENECA PLC posted the faster year-over-year revenue change (11.7% vs 1.5%).
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The Procter & Gamble Company (P&G) is an American multinational consumer goods corporation incorporated and headquartered in Cincinnati, Ohio.
AZN vs PG — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $14.5B | $22.2B |
| Net Profit | $2.4B | $4.3B |
| Gross Margin | 82.9% | 51.2% |
| Operating Margin | 24.3% | 24.2% |
| Net Margin | 16.9% | 19.4% |
| Revenue YoY | 11.7% | 1.5% |
| Net Profit YoY | 27.0% | -6.7% |
| EPS (diluted) | $1.57 | $1.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $22.2B | ||
| Q3 25 | — | $22.4B | ||
| Q2 25 | $14.5B | $20.9B | ||
| Q1 25 | — | $19.8B | ||
| Q4 24 | — | $21.9B | ||
| Q3 24 | — | $21.7B | ||
| Q2 24 | $12.9B | $20.5B | ||
| Q1 24 | — | $20.2B |
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | $2.4B | $3.6B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | — | $4.6B | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | $1.9B | $3.1B | ||
| Q1 24 | — | $3.8B |
| Q4 25 | — | 51.2% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | 82.9% | 49.1% | ||
| Q1 25 | — | 51.0% | ||
| Q4 24 | — | 52.4% | ||
| Q3 24 | — | 52.1% | ||
| Q2 24 | 83.1% | 49.6% | ||
| Q1 24 | — | 51.2% |
| Q4 25 | — | 24.2% | ||
| Q3 25 | — | 26.2% | ||
| Q2 25 | 24.3% | 20.8% | ||
| Q1 25 | — | 23.0% | ||
| Q4 24 | — | 26.2% | ||
| Q3 24 | — | 26.7% | ||
| Q2 24 | 21.2% | 18.9% | ||
| Q1 24 | — | 22.1% |
| Q4 25 | — | 19.4% | ||
| Q3 25 | — | 21.2% | ||
| Q2 25 | 16.9% | 17.3% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 21.2% | ||
| Q3 24 | — | 18.2% | ||
| Q2 24 | 14.9% | 15.3% | ||
| Q1 24 | — | 18.6% |
| Q4 25 | — | $1.78 | ||
| Q3 25 | — | $1.95 | ||
| Q2 25 | $1.57 | $1.48 | ||
| Q1 25 | — | $1.54 | ||
| Q4 24 | — | $1.88 | ||
| Q3 24 | — | $1.61 | ||
| Q2 24 | $1.24 | $1.27 | ||
| Q1 24 | — | $1.52 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.1B | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $44.8B | $53.3B |
| Total Assets | $112.4B | $127.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $7.1B | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $6.9B | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $53.3B | ||
| Q3 25 | — | $53.6B | ||
| Q2 25 | $44.8B | $52.3B | ||
| Q1 25 | — | $52.5B | ||
| Q4 24 | — | $51.4B | ||
| Q3 24 | — | $52.1B | ||
| Q2 24 | $39.6B | $50.6B | ||
| Q1 24 | — | $50.3B |
| Q4 25 | — | $127.3B | ||
| Q3 25 | — | $127.6B | ||
| Q2 25 | $112.4B | $125.2B | ||
| Q1 25 | — | $123.0B | ||
| Q4 24 | — | $122.6B | ||
| Q3 24 | — | $126.5B | ||
| Q2 24 | $104.3B | $122.4B | ||
| Q1 24 | — | $119.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $5.0B |
| Free Cash FlowOCF − Capex | — | $3.8B |
| FCF MarginFCF / Revenue | — | 17.1% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | — | 1.15× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.8B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $3.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $4.3B | ||
| Q2 24 | — | $5.8B | ||
| Q1 24 | — | $4.1B |
| Q4 25 | — | $3.8B | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | — | $4.0B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $3.9B | ||
| Q3 24 | — | $3.3B | ||
| Q2 24 | — | $5.0B | ||
| Q1 24 | — | $3.3B |
| Q4 25 | — | 17.1% | ||
| Q3 25 | — | 18.8% | ||
| Q2 25 | — | 19.1% | ||
| Q1 25 | — | 14.4% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | — | 15.2% | ||
| Q2 24 | — | 24.2% | ||
| Q1 24 | — | 16.3% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 4.8% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | — | 4.2% | ||
| Q3 24 | — | 4.6% | ||
| Q2 24 | — | 3.8% | ||
| Q1 24 | — | 3.9% |
| Q4 25 | — | 1.15× | ||
| Q3 25 | — | 1.14× | ||
| Q2 25 | — | 1.38× | ||
| Q1 25 | — | 0.98× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 1.09× | ||
| Q2 24 | — | 1.83× | ||
| Q1 24 | — | 1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZN
Segment breakdown not available.
PG
| Fabric Home Care Segment | $7.7B | 35% |
| Baby Feminine Family Care Segment | $5.1B | 23% |
| Beauty Segment | $4.0B | 18% |
| Health Care Segment | $3.4B | 15% |
| Grooming Segment | $1.8B | 8% |
